SUPN – Supernus Pharmaceuticals Inc
SUPN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.69
Margin Of Safety %
-21
Put/Call OI Ratio
1.38
EPS Next Q Diff
-0.34
EPS Last/This Y
3.05
EPS This/Next Y
1.85
Price
50.96
Target Price
63.17
Analyst Recom
1.33
Performance Q
3.16
Upside
-146.7%
Beta
0.69
Ticker: SUPN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | SUPN | 54.21 | 0.68 | 0.00 | 4722 |
| 2026-03-10 | SUPN | 53.64 | 0.66 | 0.00 | 4826 |
| 2026-03-11 | SUPN | 53.16 | 0.66 | 0.00 | 4827 |
| 2026-03-12 | SUPN | 50.47 | 0.66 | 0.00 | 4827 |
| 2026-03-13 | SUPN | 50.46 | 0.66 | 0.00 | 4827 |
| 2026-03-17 | SUPN | 50.84 | 0.66 | 0.01 | 4836 |
| 2026-03-18 | SUPN | 49.3 | 0.63 | 100.67 | 4970 |
| 2026-03-20 | SUPN | 47.8 | 0.72 | 193.00 | 4063 |
| 2026-03-25 | SUPN | 50.05 | 1.38 | 3.00 | 2038 |
| 2026-03-26 | SUPN | 50.81 | 1.39 | 0.13 | 2050 |
| 2026-03-27 | SUPN | 49.56 | 1.38 | 999.99 | 2058 |
| 2026-03-30 | SUPN | 49.36 | 1.38 | 999.99 | 2058 |
| 2026-03-31 | SUPN | 51.7 | 1.38 | 999.99 | 2058 |
| 2026-04-01 | SUPN | 51.36 | 1.38 | 999.99 | 2058 |
| 2026-04-06 | SUPN | 50.56 | 1.38 | 999.99 | 2059 |
| 2026-04-07 | SUPN | 50.96 | 1.38 | 0.20 | 2060 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | SUPN | 54.19 | -41.5 | - | 2.37 |
| 2026-03-10 | SUPN | 53.68 | -41.5 | - | 2.37 |
| 2026-03-11 | SUPN | 53.17 | -41.5 | - | 2.37 |
| 2026-03-12 | SUPN | 50.49 | -41.5 | - | 2.37 |
| 2026-03-13 | SUPN | 49.90 | -41.5 | - | 2.37 |
| 2026-03-17 | SUPN | 50.82 | -41.5 | - | 2.37 |
| 2026-03-18 | SUPN | 49.26 | -41.5 | - | 2.37 |
| 2026-03-19 | SUPN | 48.83 | -41.5 | - | 2.37 |
| 2026-03-20 | SUPN | 47.81 | -41.5 | - | 2.37 |
| 2026-03-23 | SUPN | 49.20 | -41.5 | - | 2.37 |
| 2026-03-24 | SUPN | 49.33 | -41.5 | - | 2.37 |
| 2026-03-25 | SUPN | 50.06 | -41.5 | - | 2.37 |
| 2026-03-26 | SUPN | 50.80 | -41.5 | - | 2.37 |
| 2026-03-27 | SUPN | 49.59 | -41.5 | - | 2.37 |
| 2026-03-30 | SUPN | 49.40 | -41.5 | - | 2.37 |
| 2026-03-31 | SUPN | 51.69 | -41.5 | - | 2.37 |
| 2026-04-01 | SUPN | 51.38 | -41.5 | - | 2.37 |
| 2026-04-02 | SUPN | 50.45 | -41.5 | - | 2.37 |
| 2026-04-06 | SUPN | 50.54 | -41.5 | - | 2.37 |
| 2026-04-07 | SUPN | 50.96 | -41.5 | - | 2.37 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | SUPN | -7.35 | -5.08 | 7.38 |
| 2026-03-10 | SUPN | -7.47 | -5.08 | 7.38 |
| 2026-03-11 | SUPN | -7.47 | -5.08 | 7.49 |
| 2026-03-12 | SUPN | -7.47 | -5.08 | 7.49 |
| 2026-03-13 | SUPN | -7.47 | -5.08 | 7.49 |
| 2026-03-18 | SUPN | -8.43 | -5.07 | 7.49 |
| 2026-03-19 | SUPN | -11.23 | -5.07 | 7.49 |
| 2026-03-20 | SUPN | -11.23 | -5.07 | 7.49 |
| 2026-03-23 | SUPN | -11.23 | -4.72 | 7.49 |
| 2026-03-24 | SUPN | -10.81 | -4.72 | 7.49 |
| 2026-03-25 | SUPN | -10.05 | -4.72 | 7.69 |
| 2026-03-26 | SUPN | -10.05 | -4.72 | 7.69 |
| 2026-03-27 | SUPN | -10.05 | -4.72 | 7.69 |
| 2026-03-30 | SUPN | -10.05 | -4.76 | 7.69 |
| 2026-03-31 | SUPN | -10.05 | -4.76 | 7.69 |
| 2026-04-01 | SUPN | -9.78 | -4.76 | 7.69 |
| 2026-04-02 | SUPN | -9.55 | -4.76 | 7.69 |
| 2026-04-06 | SUPN | -8.44 | -5.16 | 7.69 |
| 2026-04-07 | SUPN | -8.44 | -5.16 | 7.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.88
Avg. EPS Est. Current Quarter
0.26
Avg. EPS Est. Next Quarter
0.54
Insider Transactions
-8.44
Institutional Transactions
-5.16
Beta
0.69
Average Sales Estimate Current Quarter
192
Average Sales Estimate Next Quarter
211
Fair Value
40.5
Quality Score
49
Growth Score
65
Sentiment Score
91
Actual DrawDown %
14.6
Max Drawdown 5-Year %
-45.9
Target Price
63.17
P/E
Forward P/E
14.46
PEG
0.85
P/S
4.08
P/B
2.76
P/Free Cash Flow
63.8
EPS
-0.68
Average EPS Est. Cur. Y
2.37
EPS Next Y. (Est.)
4.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-5.36
Relative Volume
1.18
Return on Equity vs Sector %
-31.1
Return on Equity vs Industry %
-10.9
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.13
EBIT Estimation
◆
SUPN
Healthcare
$50.96
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
50.5
Range 1M
44%
Sup Dist
2.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-40.5%
EPS NY
83.2%
52W%
71.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+93.6% upside
Upside
+93.6%
Quality
49
MoS
-21%
Supernus Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 778
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
SUPN
Latest News
—
Caricamento notizie per SUPN…
stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today
news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance
stock history SUPN – Supernus Pharmaceuticals Inc invest stock market
stock prices SUPN premarket after hours
ticker SUPN fair value insiders trading